44
decreases in hospitalizations and surgeries as well as improving quality of life. It
is not known at this time if the anti-TNFs alter the natural history of CD. While
anti-TNFs have been approved for CD since 1998, longer follow-up data is needed
to determine if the natural history of CD can be altered. Improvements in thera-
peutic strategies including combination therapy and therapeutic drug monitoring
will likely continue to improve outcomes and reduce side effects of anti-TNF
usage.
References
- Baert FJ, D’Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, et al. Tumor necrosis
factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in
Crohn’s ileocolitis. Gastroenterology. 1999;116(1):22–8. - Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–78.
- Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor
alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339(8785):89–91. - Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necro-
sis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel
disease. Gastroenterology. 1994;106(6):1455–66. - Lukacs NW, Chensue SW, Strieter RM, Warmington K, Kunkel SL. Inflammatory granuloma
formation is mediated by TNF-alpha-inducible intercellular adhesion molecule-1. J Immunol.
1994;152(12):5883–9. - Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and
initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol.
1993;30(16):1443–53. - Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclo-
nal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector
functions. Cytokine. 1995;7(3):251–9. - Derkx B, Taminiau J, Radema S, Stronkhorst A, Wortel C, Tytgat G, et al. Tumour-necrosis-
factor antibody treatment in Crohn’s disease. Lancet. 1993;342(8864):173–4. - van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, et al.
Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody
(cA2). Gastroenterology. 1995;109(1):129–35. - Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-
term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s
disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35. - Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and
safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remis-
sion in Crohn’s disease. Gastroenterology. 1999;117(4):761–9. - Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al.
Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet.
2002;359(9317):1541–9. - Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al.
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease.
Gastroenterology. 2004;126(2):402–13. - Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D,
et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med.
2010;362(15):1383–95.
B. P. Va u g h n